Advances in bioconjugation for next-generation therapeutics

Discover how advances in bioconjugation are transforming the design and optimization of next-generation therapeutics. In this SelectScience interview, Matthew Giese, Bioconjugate Field Application Scientist at Vector Laboratories, discusses the latest innovations shaping the field and explains how they are enabling greater precision and control over conjugate structure and function. Through customer examples spanning cancer vaccines, siRNA delivery, radiopharmaceuticals, cell therapy workflows, and multiplexed immunofluorescence, Matthew highlights the value of end-to-end bioconjugation solutions in streamlining development and optimization.

This video was filmed at AACR Annual Meeting 2026.